Literature DB >> 31819704

Are we finally moving toward personalized therapy in colorectal cancer?

S Gill1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31819704      PMCID： PMC6878936          DOI： 10.3747/co.26.5943

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  2 in total

1.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Authors:  Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Briant Fruth; Jeffrey A Meyerhardt; Deborah Schrag; Claire Greene; Bert H O'Neil; James Norman Atkins; Scott Berry; Blase N Polite; Eileen M O'Reilly; Richard M Goldberg; Howard S Hochster; Richard L Schilsky; Monica M Bertagnolli; Anthony B El-Khoueiry; Peter Watson; Al B Benson; Daniel L Mulkerin; Robert J Mayer; Charles Blanke
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

2.  What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer?

Authors:  Y J Ko; M Abdelsalam; P Kavan; H Lim; P A Tang; M Vincent; R Wong; M Kish; S Gill
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.